(NASDAQ: OPTN) Optinose's forecast annual revenue growth rate of 29.94% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Optinose's revenue in 2024 is $70,987,000.On average, 3 Wall Street analysts forecast OPTN's revenue for 2024 to be $10,236,213,007, with the lowest OPTN revenue forecast at $9,560,753,174, and the highest OPTN revenue forecast at $10,671,499,330. On average, 3 Wall Street analysts forecast OPTN's revenue for 2025 to be $14,141,510,877, with the lowest OPTN revenue forecast at $11,623,406,533, and the highest OPTN revenue forecast at $15,737,448,078.
In 2026, OPTN is forecast to generate $17,444,459,894 in revenue, with the lowest revenue forecast at $13,833,633,672 and the highest revenue forecast at $20,727,920,160.